Natasha E. Daughtrey

William G. James, II

Gregory D. Miller

Jenna Z. Gabay

Jenny J. Zhang

Andrew Chalson

F. Dominic Cerrito

Evangeline Shih

William C. Baton

Charles M. Lizza

Sarah Ann Sullivan

Gabriel P. Brier

Eric C. Stops

Matthew J. Hertko

David L. Moses

Marta Godecki

Brian J. Forsatz

Frank C. Calvosa

Cary Miller

ANDA filing triggers Celgene challenge to Hikma's generic THALOMID®, accused of infringing nine patents on its REMS safety system using a `prescription approval code`.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Quinn Emanuel Urquhart & Sullivan LLP	L5 A
F. Dominic Cerrito	L5 A
Evangeline Shih	L4 A
Eric C. Stops	L4 C
Andrew Chalson	L2 A
Frank C. Calvosa	L2 A
Gabriel P. Brier	L2 C
Brian J. Forsatz	L2 C
Marta Godecki	L1 B
Jones Day	L5 A
Matthew J. Hertko	L3 C
Cary Miller	L1 B
Saul Ewing LLP	L3 B
William C. Baton	L5 A
Charles M. Lizza	L5 A
Sarah Ann Sullivan	L5 A
David L. Moses	L3 B

Name	Ratings
Hikma Pharmaceuticals Intl Ltd	L3 D
Hikma Pharmaceuticals USA Inc	L3 D

Name	Ratings
Goodwin Procter LLP	L4 C
William G. James, II	L4 E
Natasha E. Daughtrey	L2 E
Jenny J. Zhang	-- -- --
Rivkin Radler LLPLocal	L2 C
Gregory D. Miller	L2 B
Jenna Z. Gabay	L1 C

2:18-cv-13477

Celgene Corp v. Hikma Pharma Intl Ltd